Braveheart Investment Group plc Update on the Pharm2Farm anti-viral mask project
September 18 2020 - 2:00AM
RNS Non-Regulatory
TIDMBRH
Braveheart Investment Group plc
18 September 2020
RNS Reach announcement (non-regulatory)
18 September 2020
Braveheart Investment Group plc
("Braveheart" or the "Group")
Update on the P harm2Farm anti-viral mask project
Braveheart Investment Group (AIM: BRH), is pleased to announce
that Pharm 2 Farm Limited ("P2F") has placed an order for an
automated face mask production line which is expected to be
delivered in November 2020 and commissioned by the end of December
2020.
The face mask production line, which is manufactured in Europe,
has the capacity to produce up to five million standard or
anti-viral face masks per month.
Conventional surgical type masks typically comprise of three
layers, with the inner layer acting as a physical barrier to
viruses and bacteria. However, they are only recommended for up to
two hours of continual use as this layer can become moist and fail,
thereby allowing the virus to penetrate though. P2F has developed a
second defensive layer that incorporates its own nanotechnology,
which is engineered to kill viruses and bacteria. Combining this
new active layer with the physical barrier layer, to produce four
layer (ply) masks, is expected to improve user safety over a
prolonged use. This new material is currently undergoing testing,
specifically, with respect to the time taken to kill viruses,
including COVID-19. These tests are, being undertaken at the
University of Nottingham and results are expected by the beginning
of October. Following a satisfactory outcome of the tests
undertaken at the University of Nottingham, it is envisaged that
manufacture of the anti-viral face masks will commence in the first
quarter of 2021. In the event that these tests do not provide a
satisfactory outcome, the production line will be used to produce
conventional surgical type masks, which P2F believe could still be
produced on a profitable basis.
For further
information:
Braveheart Investment Group plc Tel: 01738 587555
Viv Hallam, Executive Director
Allenby Capital Limited (Nominated Adviser Tel: 020 3328 5656
and Joint Broker)
David Worlidge / James Hornigold
Peterhouse Capital Limited (Joint Broker) Tel: 020 7469 0936
Heena Karani / Lucy Williams
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor
communication service aimed at assisting listed and unlisted
(including AIM quoted) companies to distribute non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Private
Policy.
END
NRAGPUGWBUPUPWM
(END) Dow Jones Newswires
September 18, 2020 02:00 ET (06:00 GMT)
Braveheart Investment (LSE:BRH)
Historical Stock Chart
From Apr 2024 to May 2024
Braveheart Investment (LSE:BRH)
Historical Stock Chart
From May 2023 to May 2024